Not found

Peter Zage, MD, PhD

Assistant Affiliate Member, Research Institute
Houston Methodist


Biography

Dr. Zage graduated from The Johns Hopkins University in 1990 with a B.A. degree in biology and subsequently received his M.D. and Ph.D. degrees from Columbia University in New York. He completed a residency in pediatrics at the University of Chicago Children's Hospital, followed by a fellowship in pediatric hematology/oncology at the Children's Memorial Hospital in Chicago. During his fellowship, he developed an interest in the pathogenesis of pediatric solid tumors, particularly neuroblastoma and retinoblastoma. He was an Assistant Professor in the Division of Pediatrics at M. D. Anderson Cancer Center from 2006 to 2011, where he also served as a research co-director of the Retinoblastoma Center of Houston. He became a member of The Methodist Hospital Research Institute in 2008. In 2011, Dr. Zage accepted a position as an Assistant Professor at Baylor College of Medicine and as a member of the solid tumor and developmental therapeutics teams at Texas Children's Hospital.

Dr. Zage continues to serve as a co-director of the Retinoblastoma Center of Houston and is an adjunct member of the Neuroscience program at the University of Texas Graduate School of Biomedical Sciences. He was awarded the Young Investigator Award from the American Society of Pediatric Hematology/Oncology in 2009 for his research focused on novel therapies for children with solid tumors in general and neuroblastoma in particular.

Description of Research

Dr. Zage's laboratory is primarily interested in evaluating the efficacy of novel therapies for children with neuroblastoma, retinoblastoma and other childhood solid tumors and in understanding the critical genetic and molecular events that could be used as targets for new treatments. He is developing a comprehensive program for the treatment of children with recurrent or refractory neuroblastoma, including chemotherapy, novel biologically targeted agents and immunotherapy. he collaborates with other institutions in the development of innovative approaches to treatments for all children with cancer.

Areas Of Expertise

Retinoblastoma Neuroblastoma Developmental therapeutics
Education & Training

PhD, Columbia University Graduate School of Arts and Sciences, New York, NY
Publications

Sociodemographic and clinical characteristics associated with vitamin D status in newly diagnosed pediatric cancer patients
Aristizabal, P, Sherer, M, Perdomo, BP, Castelao, E, Thornburg, CD, Proudfoot, J, Jacobs, E, Newfield, RS, Zage, P, Roberts, W & Martinez, ME 2020, Pediatric Hematology and Oncology, vol. 37, no. 4, pp. 314-325. https://doi.org/10.1080/08880018.2020.1721629

The potential functional roles of nme1 histidine kinase activity in neuroblastoma pathogenesis
Adam, K, Lesperance, J, Hunter, T & Zage, P 2020, International journal of molecular sciences, vol. 21, no. 9, 3319. https://doi.org/10.3390/ijms21093319

Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways
Subramonian, D, Phanhthilath, N, Rinehardt, H, Flynn, S, Huo, Y, Zhang, J, Messer, K, Mo, Q, Huang, S, Lesperance, J & Zage, P 2020, British Journal of Cancer. https://doi.org/10.1038/s41416-020-0905-8

A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma
Lewis, EC, Kraveka, JM, Ferguson, W, Eslin, D, Brown, VI, Bergendahl, G, Roberts, W, Wada, RK, Oesterheld, J, Mitchell, D, Foley, J, Zage, P, Rawwas, J, Rich, M, Lorenzi, E, Broglio, K, Berry, D & Saulnier Sholler, GL 2020, International Journal of Cancer. https://doi.org/10.1002/ijc.33044

Mechanisms of Efficacy of the FGFR1–3 Inhibitor AZD4547 in Pediatric Solid Tumor Models
Phanhthilath, N, Hakim, S, Su, C, Liu, A, Subramonian, D, Lesperance, J & Zage, P 2020, Investigational new drugs. https://doi.org/10.1007/s10637-020-00933-2

The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo
Flynn, SM, Lesperance, J, Macias, A, Phanhthilath, N, Paul, MR, Kim, JW, Tamayo, P & Zage, P 2019, Oncotarget, vol. 10, no. 59, pp. 6323-6333.

Maintenance DFMO Increases Survival in High Risk Neuroblastoma
Sholler, GLS, Ferguson, W, Bergendahl, G, Bond, JP, Neville, K, Eslin, D, Brown, V, Roberts, W, Wada, RK, Oesterheld, J, Mitchell, D, Foley, J, Parikh, NS, Eshun, F, Zage, P, Rawwas, J, Sencer, S, Pankiewicz, D, Quinn, M, Rich, M, Junewick, J & Kraveka, JM 2018, Scientific reports, vol. 8, no. 1, 14445. https://doi.org/10.1038/s41598-018-32659-w

Overview and recent advances in the treatment of neuroblastoma
Whittle, SB, Smith, V, Doherty, E, Zhao, S, McCarty, S & Zage, P 2017, Expert Review of Anticancer Therapy, vol. 17, no. 4, pp. 369-386. https://doi.org/10.1080/14737140.2017.1285230

CD114: A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family
Zage, P, Whittle, SB & Shohet, JM 2017, Journal of Cellular Biochemistry, vol. 118, no. 2, pp. 221-231. https://doi.org/10.1002/jcb.25656

The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma
Whittle, SB, Patel, K, Zhang, L, Woodfield, SE, du, M, Smith, V & Zage, P 2016, Investigational New Drugs, pp. 1-8. https://doi.org/10.1007/s10637-016-0387-y

Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine
Du, M, Zhang, L, Scorsone, KA, Woodfield, SE & Zage, P 2016, Scientific reports, vol. 6, 27458. https://doi.org/10.1038/srep27458

Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression
Woodfield, SE, Zhang, L, Scorsone, KA, Liu, Y & Zage, P 2016, BMC Cancer, vol. 16, no. 1, 172. https://doi.org/10.1186/s12885-016-2199-z

A polymorphism in the FGFR4 gene is associated with risk of neuroblastoma and altered receptor degradation
Whittle, SB, Reyes, S, Du, M, Gireud, M, Zhang, L, Woodfield, SE, Ittmann, M, Scheurer, ME, Bean, AJ & Zage, P 2016, Journal of Pediatric Hematology/Oncology, vol. 38, no. 2, pp. 131-138. https://doi.org/10.1097/MPH.0000000000000506

Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition
Zhang, L, Scorsone, K, Woodfield, SE & Zage, P 2015, Cancer Chemotherapy and Pharmacology, vol. 76, no. 5, pp. 977-987. https://doi.org/10.1007/s00280-015-2871-z

CD114 expression mediates melanoma tumor cell growth and treatment resistance
Zhang, L, Agarwal, S, Shohet, JM & Zage, P 2015, Anticancer Research, vol. 35, no. 7, pp. 3787-3792.

MTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling
Zhang, H, Dou, J, Yu, Y, Zhao, Y, Fan, Y, Cheng, J, Xu, X, Liu, W, Guan, S, Chen, Z, Shi, Y, Patel, R, Vasudevan, SA, Zage, P, Zhang, H, Nuchtern, JG, Kim, ES, Fu, S & Yang, J 2015, Apoptosis, vol. 20, no. 1, pp. 50-62. https://doi.org/10.1007/s10495-014-1066-0

The novel kinase inhibitor EMD1214063 is effective against neuroblastoma
Scorsone, K, Zhang, L, Woodfield, SE, Hicks, J & Zage, P 2014, Investigational New Drugs, vol. 32, no. 5, pp. 815-824. https://doi.org/10.1007/s10637-014-0107-4

Congenital neuroblastoma in a neonate with isotretinoin embryopathy
Aguilar, S, Louis, C, Hicks, J, Zage, P & Russell, H 2014, Journal of pediatric hematology/oncology, vol. 36, no. 2. https://doi.org/10.1097/MPH.0b013e318290c39e

UBE4B protein couples ubiquitination and sorting machineries to enable epidermal growth factor receptor (EGFR) degradation
Sirisaengtaksin, N, Gireud, M, Yan, Q, Kubota, Y, Meza, D, Waymire, JC, Zage, P & Bean, AJ 2014, Journal of Biological Chemistry, vol. 289, no. 5, pp. 3026-3039. https://doi.org/10.1074/jbc.M113.495671

Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system
Stricker, TP, Morales La Madrid, A, Chlenski, A, Guerrero, L, Salwen, HR, Gosiengfiao, Y, Perlman, EJ, Furman, W, Bahrami, A, Shohet, JM, Zage, PE, Hicks, MJ, Shimada, H, Suganuma, R, Park, JR, So, S, London, WB, Pytel, P, Maclean, KH & Cohn, SL 2014, Molecular Oncology, vol. 8, no. 3, pp. 669-678. https://doi.org/10.1016/j.molonc.2014.01.010

Live Chat Available